Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients

Overview

Journal Cancer Cell

Publisher Cell Press

Specialty Oncology

Date 2021 Jan 21

PMID 33476581

Citations 71

Authors

Sultan Abdul-Jawad

Luca Bau

Thanussuyah Alaguthurai

Irene Del Molino Del Barrio

Adam G Laing

Thomas S Hayday

Leticia Monin

Miguel Munoz-Ruiz

Louisa McDonald

Isaac Francos Quijorna

Duncan McKenzie

Richard Davis

Anna Lorenc

Julie Nuo En Chan

Sarah Ryan

Eva Bugallo-Blanco

Rozalyn Yorke

Shraddha Kamdar

Matthew Fish

Iva Zlatareva

Pierre Vantourout

Aislinn Jennings

Sarah Gee

Katie Doores

Katharine Bailey

Sophie Hazell

Julien de Naurois

Charlotte Moss

Beth Russell

Aadil A Khan

Mark Rowley

Reuben Benjamin

Deborah Enting

Doraid Alrifai

Yin Wu

You Zhou

Paul Barber

Tony Ng

James Spicer

Mieke Van Hemelrijck

Mayur Kumar

Jennifer Vidler

Yadanar Lwin

Paul Fields

Sophia N Karagiannis

Anthony C C Coolen

Anne Rigg

Sophie Papa

Adrian C Hayday

Piers E M Patten

Sheeba Irshad

Affiliations

Soon will be listed here.

Abstract

Given the immune system's importance for cancer surveillance and treatment, we have investigated how it may be affected by SARS-CoV-2 infection of cancer patients. Across some heterogeneity in tumor type, stage, and treatment, virus-exposed solid cancer patients display a dominant impact of SARS-CoV-2, apparent from the resemblance of their immune signatures to those for COVID-19 non-cancer patients. This is not the case for hematological malignancies, with virus-exposed patients collectively displaying heterogeneous humoral responses, an exhausted T cell phenotype and a high prevalence of prolonged virus shedding. Furthermore, while recovered solid cancer patients' immunophenotypes resemble those of non-virus-exposed cancer patients, recovered hematological cancer patients display distinct, lingering immunological legacies. Thus, while solid cancer patients, including those with advanced disease, seem no more at risk of SARS-CoV-2-associated immune dysregulation than the general population, hematological cancer patients show complex immunological consequences of SARS-CoV-2 exposure that might usefully inform their care.

Citing Articles

Impaired SARS-CoV-2-Specific CD8+ T Cells After Infection or Vaccination but Robust Hybrid T Cell Immunity in Patients with Multiple Myeloma.

Shoumariyeh K, Csernalabics B, Salimi Alizei E, Reinscheid M, Giese S, Ciminski K Vaccines (Basel). 2024; 12(11).

PMID: 39591152 PMC: 11598869. DOI: 10.3390/vaccines12111249.

Factors Associated with IgG/IgM Levels after SARS-CoV-2 Vaccination in Patients with Head and Neck Cancer.

Liao W, Liang H, Liang Y, Gao X, Liao G, Cai S Trop Med Infect Dis. 2024; 9(10).

PMID: 39453261 PMC: 11511189. DOI: 10.3390/tropicalmed9100234.

Association of immune checkpoint inhibitors with SARS-CoV-2 infection rate and prognosis in patients with solid tumors: a systematic review and meta-analysis.

Sun L, Zhao F, Xiang Y, Chen S, Shu Q Front Immunol. 2024; 15:1259112.

PMID: 38887296 PMC: 11180804. DOI: 10.3389/fimmu.2024.1259112.

Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID-19 pandemic: A population-based, nation-wide study.

Faitova T, Brieghel C, Eriksson F, Niemann C Hemasphere. 2024; 8(3):e57.

PMID: 38505245 PMC: 10949075. DOI: 10.1002/hem3.57.

The Impact COVID-19 Infection on Cancer Patients: A Tertiary Cancer Center Experience in Jordan.

Al-Rabi K, Al-Qadi F, Al-Ibraheem A, Halahleh K, Salah S, Ababneh H Cureus. 2024; 15(12):e51310.

PMID: 38288187 PMC: 10823193. DOI: 10.7759/cureus.51310.

References

de Lima C, Mirandolli T, Carneiro L, Tusset C, Romer C, Andreolla H . Prolonged respiratory viral shedding in transplant patients. Transpl Infect Dis. 2013; 16(1):165-9. PMC: 7169780. DOI: 10.1111/tid.12167. View

Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C . Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4):420-422. PMC: 7164771. DOI: 10.1016/S2213-2600(20)30076-X. View

Cooper N, Arnold D . The effect of rituximab on humoral and cell mediated immunity and infection in the treatment of autoimmune diseases. Br J Haematol. 2010; 149(1):3-13. DOI: 10.1111/j.1365-2141.2010.08076.x. View

Gralinski L, Baric R . Molecular pathology of emerging coronavirus infections. J Pathol. 2014; 235(2):185-95. PMC: 4267971. DOI: 10.1002/path.4454. View

Oren S, Mandelboim M, Braun-Moscovici Y, Paran D, Ablin J, Litinsky I . Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2007; 67(7):937-41. DOI: 10.1136/ard.2007.077461. View

Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R . The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020; 21(8):1023-1034. PMC: 7417808. DOI: 10.1016/S1470-2045(20)30388-0. View

Williamson E, Walker A, Bhaskaran K, Bacon S, Bates C, Morton C . Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. PMC: 7611074. DOI: 10.1038/s41586-020-2521-4. View

Guilpain P, Le Bihan C, Foulongne V, Taourel P, Pansu N, Maria A . Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis. 2020; 80(1):e10. DOI: 10.1136/annrheumdis-2020-217549. View

Lucas C, Wong P, Klein J, Castro T, Silva J, Sundaram M . Longitudinal analyses reveal immunological misfiring in severe COVID-19. Nature. 2020; 584(7821):463-469. PMC: 7477538. DOI: 10.1038/s41586-020-2588-y. View

10.

Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y . Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. Cell Discov. 2020; 6:31. PMC: 7197635. DOI: 10.1038/s41421-020-0168-9. View

11.

Brouwer P, Caniels T, van der Straten K, Snitselaar J, Aldon Y, Bangaru S . Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science. 2020; 369(6504):643-650. PMC: 7299281. DOI: 10.1126/science.abc5902. View

12.

Choi B, Choudhary M, Regan J, Sparks J, Padera R, Qiu X . Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host. N Engl J Med. 2020; 383(23):2291-2293. PMC: 7673303. DOI: 10.1056/NEJMc2031364. View

13.

Ueda M, Martins R, Hendrie P, McDonnell T, Crews J, Wong T . Managing Cancer Care During the COVID-19 Pandemic: Agility and Collaboration Toward a Common Goal. J Natl Compr Canc Netw. 2020; :1-4. DOI: 10.6004/jnccn.2020.7560. View

14.

Pinato D, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R . Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov. 2020; . PMC: 7668225. DOI: 10.1158/2159-8290.CD-20-0773. View

15.

Pickering S, Betancor G, Galao R, Merrick B, Signell A, Wilson H . Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathog. 2020; 16(9):e1008817. PMC: 7514033. DOI: 10.1371/journal.ppat.1008817. View

16.

McLane L, Abdel-Hakeem M, Wherry E . CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. Annu Rev Immunol. 2019; 37:457-495. DOI: 10.1146/annurev-immunol-041015-055318. View

17.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin J, Olsson A . Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020; 183(1):158-168.e14. PMC: 7427556. DOI: 10.1016/j.cell.2020.08.017. View

18.

Shah V, Ko T, Zuckerman M, Vidler J, Sharif S, Mehra V . Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. Br J Haematol. 2020; 190(5):e279-e282. PMC: 7307054. DOI: 10.1111/bjh.16935. View

19.

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

20.

Amanat F, Stadlbauer D, Strohmeier S, Nguyen T, Chromikova V, McMahon M . A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020; 26(7):1033-1036. PMC: 8183627. DOI: 10.1038/s41591-020-0913-5. View